Member Info for LovableLumax

A vote on consolidation and then a raise if they can get one away

Given the £400k FY25 revenue any contracts that are expected to generate £40k are subject to an RNS so a fair few of these are needed and soon to satisfy the auditor and give IIs any confidence that they won't be throwing good money after bad in a raise.

Unless some contract RNSs drop the The company's market cap will continue to drop circa £200k a month as the market rightly attributes no value to the IP and as of today they likely have £800,000 or less in cash. If they leave the audit to end of May or early June they will have a month's cash and the auditor (unless there are signed contracts from large cos) will want a 12 months' cash (£2.6m) on the balance sheet to sign the accounts off as a going concern. The question is will IIs step up again as retail will surely be unable to.

See if the new BOD is able to convert their leads into contracts and needed ASAP or it's goodnight.

Fortport, that tickled me, derisk in June!!! Large contracts needed ASAP as the auditor won’t be signing anything off.

I suggest it’s immaterial if Enhertu’s patent expires in 7 years as if 6103 performs as expected/hoped in clinic enhertu will be in trouble before that. 6103 would go up against it in a competitor arm and if is performs as it has enhertu will be redundant or will start that journey.

Optic, you said - Its never ending placings over there for 'general working capital'.

I can only assume you're unaware of what happens here in March/April before every audit sig off? A raise for working capital.

Https://x.com/jstonker/status/2023043387067347320?s=46

The comments on here re up 15% when the spread has been that or MMs disguising buys is like idiots suggesting MMs manipulate all the time.

You can buy below mid price because there is little demand for shares.

Fair point re my posting on here but at least most of it rational.

Mirriad need some chunky contracts and soon to get their audit signed off. Who knows maybe the new CEO will deliver.

MMs disguising buys as sells, what the feck. This BB. like Mirriad is for dimwits. Any trade below mid price will show as a sell and any trade above will show as a buy. If I'm holding shares in a co I much prefer sells to look like buys so MMs happy to take shares above mid. Unless there is some news soon there it will drop further as with every month the cash runway recedes. I can't see IIs supporting a raise so there'll have to be large appetite from retail which I also can't see. We'll surely know if not this month early next.

We won’t know for sure if the superb preclinical work will replicate in clinic but all the lab work suggests there are no issues with cleaving.

Sustained release mechanism in the tumor is highly effective: The sustained release mechanism produces a maximum concentration (Cmax) of released exatecan, with exposure duration of over five days in the tumor, with plasma exposure gone in two hours

· High levels of antitumor activity of FAP-Exd: Multiple patient-derived xenograft models demonstrate robust antitumor activity with deeper and more durable responses than achieved with conventional exatecan

· FAP-Exd has the potential to reach a broad patient population with high unmet need: Exatecan is the most potent topoisomerase I inhibitor that has been tested in the clinic and as a pre|CISION medicine delivers exatecan directly to the tumor with the potential to address multiple indications with high unmet need

· Faster and more robust Phase 1 development using AI: The clinical development of FAP-Exd was designed using an AI approach, querying a large database to identify those cancer indications with the highest likelihood of response to the drug through co-expression of FAP and SLFN11

As mentioned on X breakthrough therapy for Ava6000 on SGC seems a certainty and I suspect if designated a partner is announced to take into P2/3. I’m sure CC has a plan and is executing.

Https://x.com/am231982/status/2018659737131225155?s=46

'We can put almost any drug on Pre|CISION' #AVCT

What are the real world impacts of this?

Case study 1 - AVA6000 the 1st Pre|CISION drug

- Uses a 50yr old warhead Doxorubicin

- Doxorubicin has a lifetime limit of 550mg/m2 limiting the number of cycles for patients.

*The FDA has just removed this life-time limit for AVA6000!!*

- Dox side effects include but not limited to cardio toxicity. AVA6000 has not seen any 'severe cardiac toxicity observed' meaning patients can safely have more cycles of AVA6000 treatment.

- Avacta SAB member Dr. Yu is a clinical cardiologist stated that he often gets young patients in their 20's and 30's coming to him with severely damaged hearts from prior treatments due to cardio toxicity but he has no treatment options left for them. AVA6000 is now a solution to this problem.

- Avacta SAB member Lee Cranmer 'We are seeing vesicant levels of Dox in the tumour'!

- 4+ years of clinical data, FDA approved this lifetime limit removal based on irrefutable clinical evidence. The biggest endorsement yet of Pre|CISION.

Case study 2 - AVA6103 the 2nd Pre|CISION drug

- Exatecan is the most potent topo1 warhead and is used in AVA6103

- NO one has safely used Exatecan in its naked form and multiple P2/3 trials failed due to toxicity.

- Pre|CISION has harnessed toxicity with exceptional preclinical results. First dose in humans is due in the coming weeks.

-AVA6103 had a therapeutic index of 75X and can remain in the tumour for over 5 days! Ground breaking.

- 99:1 tumour to plasma ratio in preclinical setting expected to improve X times in humans. Obscene.

- What happens if they can safely dose Exetecan at multiple times the typical 5mg/m2 dose, get X00% more in the tumour than plasma and replicate or better the efficacy seen in preclinical data which had 19/21 complete responses? The inevitable TO.

Case Study 3 - Dual Warhead Precision drugs (near unlimited combinations)

Case Study 4 - Putting existing approved drugs on to Pre|CISION - Limited only by the number of approved drugs! How many lifetime limits could be removed/ improved from these drugs due to improvements to their safety and tolerability which increases the chances for efficacy. Importantly new Pre|CISION drugs would extend patents.

Case study 5 - Putting drugs which failed phase 2/3 trials on Pre|CISION massive upside opportunity.

The possibilities are endless here. Well done Chris and Team.

Https://x.com/rah00084/status/2018640912671232421?s=46

Removal of the lifetime limit for doxorubicin is very important to #AVCT for several reasons:

Patients who previously had to stop receiving AVA6000 due to arbitrary cumulative limits, despite their cancer remaining at bay and toxicities in check, can now continue on drug. This will extend their PFS, the primary endpoint in P1b and P2/3.

P1b will be able to recruit a wider variety of patients (who previously would have been forced to stop treatment earlier due to their historic dosing of anthracyclines).

This is obviously of particular benefit to the TNBC indication, where competition for first and second line patients is fierce but it will also improve the PFS in P2/3 SGC.

At a base level, removal of this limit is the first concrete insight we have received into what the FDA actually thinks of AVA6000 and pre|CISION.

We have heard the FDA were historically surprised by the lack of toxicities.

Some shareholders will recall the retelling (at the AGM) of the exchange where the CEO said the FDA needed to double check the toxicity figures because they were so good(!)

This RNS is the first we have seen of the FDA going beyond ‘normal’ regulatory hurdles (ie INDs, dose escalations etc) and saying pre|CISION really is that good.

The FDA has rubber stamped pre|CISION.

Whilst the implications of this for AVA6000 are vast, the implications for pre|CISION as a platform are transformative.

Make no mistake @coughlin582’s dialogue with regulators and clinicians got us here.

Perhaps, just perhaps, when she says she may have found her ‘dent in cancer’ via AVA6103 you should start to believe her…

Blockbuster in every sense.

https://x.com/blueberrymgmnt/status/2018597022811795885?s=46

Selecting a biologic dose allows Phase 2 dosing to be based on comparative activity across dose levels rather than a single RP2D extrapolated from MTD, reducing a highly common Phase 2 failure mode.

FDA’s Project Optimus guidance states that dose-finding should include “dose- and exposure-response relationships for efficacy and safety” and that sponsors should identify an “optimal biologically active dose” rather than relying solely on maximum tolerated dose.

Collaboration.

As noted on X today's RNS will be noted by industry. FDA getting rid of a decades old lifetime dose validates the platform in Large Pharms companies eyes. Can't be understated.

Https://x.com/golfnut48846224/status/1836326493154111698?s=46

As has previously been stated -

There are no other technologies that can deliver cancer treatment drugs directly into the tumor at the concentrations that our payloads enable without causing highly toxic side effects.

Thorn understands data better than AI. Haha.

Grok is the short half-life of AVA6000 negative?

No, the short plasma half-life of the intact AVA6000 prodrug (around 30-90 minutes, with early clinical data indicating ~45 minutes or 0.85 hours in some analyses) does not negatively affect the efficacy of the cleaved (released) doxorubicin. In fact, the design of AVA6000 leverages this short half-life as part of its tumor-targeting mechanism.

AVA6000 is a first-generation pre|CISION peptide drug conjugate where the intact prodrug circulates briefly in plasma before rapid cleavage by fibroblast activation protein (FAP) in the tumor microenvironment (TME). This short systemic half-life minimizes prolonged exposure of the inactive prodrug in circulation and reduces the risk of off-target cleavage or systemic release of doxorubicin.

Key points from clinical and preclinical data (Phase 1 trial updates, including ESMO 2024 and related posters/publications):

- The intact AVA6000 is rapidly distributed and cleared (t1/2 ≈ 0.85–1.36 hours across doses), limiting its time in plasma where FAP activity is low.

- Cleavage occurs predominantly in the FAP-rich TME, leading to high local concentrations of active doxorubicin (median tumor-to-plasma ratio of ~100:1 at 24 hours post-dose in biopsies).

- The released doxorubicin shows favorable pharmacokinetics compared to conventional doxorubicin: an extended plasma half-life (~40-45% longer, e.g., from a historical ~24-36 hours to roughly 30-52+ hours depending on dose/context), reduced Cmax (~40-90% lower), and reduced volume of distribution (~40% lower). This contributes to better retention in the tumor, lower systemic toxicity, and improved tolerability.

- Efficacy signals are positive: durable responses (e.g., partial responses in sarcomas and salivary gland cancers), high disease control rates (e.g., 91% in salivary gland cancer cohorts), and antitumor activity in FAP-high tumors, despite the prodrug's short circulation time. Tumor biopsies confirm effective doxorubicin release even in tumors with varying FAP levels, as lower FAP activity is still sufficient for cleavage.

- No maximum tolerated dose (MTD) has been reached despite higher equivalent doxorubicin dosing (up to ~4x conventional), highlighting the improved therapeutic index driven by targeted release rather than prolonged prodrug circulation.

In summary, the short half-life of intact AVA6000 is intentional and beneficial — it enables safe systemic delivery with rapid, tumor-specific activation, resulting in therapeutically effective doxorubicin concentrations in the TME without compromising (and actually enhancing) overall efficacy and safety compared to standard doxorubicin.

This is based on Avacta's Phase 1 data (NCT04969835), ESMO/AACR presentations, and related analyses as of 2025 updates. For the latest details, check ongoing trial results or Avacta's publications.

- The released doxorubicin shows favorable pharmacokinetics compared to conventional doxorubicin: an extended plasma half-life (~40-45% longer, e.g., from a historical ~24-36 hours to roughly 30-52+ hours depending on dose/context), reduced Cmax (~40-90% lower), and reduced volume of distribution (~40% lower). This contributes to better retention in the tumor, lower systemic toxicity, and improved tolerability.

Off to enjoy the rest of the weekend. Ignore the FUD, those not invested with clear agendas. Cheerio

6000 worked on heavily pretreated STS patients but they’ve targeted SGC as a lower bar. If 6000 wasn’t spring on STS it would have stopped recruiting and we’d have had an RNS.

Actually no point in replying to someone not invested and now new FUD. Sold (with a justified reason re cash) and now trying to spread new FUD. Get a life. You sold. Back to ignoring the troll as best to cut your oxygen off.

6000 delivers more dox to tumours with fewer AEs. STS has a 20% response rate with dox in first line setting and is standard of care because of its PFS. Suggesting 6000 isn't working is contradicting what the data and CEO says. Dox isn’t used for SGC but we got super PFS with fewer AEs and no cardio tox so investigators wands to target TNBC as dox usually used in combo but I’m sure 6000 will do a lot better Given more dox being delivered to tumour.

Avacta chemists, CEO and investigators wouldn’t have recommended their patients take it if the data suggested half life an issue or otherwise. CC would not lie to investors, patients, colleagues and her peers. Random posters happy to lie at will.

Trebling PFS says it works better than anything else. Also PFS with fewer side effects.

There are no other technologies that can deliver cancer treatment drugs directly into the tumor at the concentrations that our payloads enable without causing highly toxic side effects.

Because AVA6000 extended dox’s half life by 40% (according to CEO and her staff) it didn’t need extending. Fap-exd did -

Tumor and plasma exposure studies have demonstrated that FAP-Exd rapidly penetrates the tumor microenvironment (TME), is held intact for over five days in the tumor and releases exatecan, with an observed high maximal concentration (Cmax) in the tumor within minutes and very low exposure in the bloodstream which is undetectable within two hours.

Yes the cash position needs addressing and that's why the share price poor. The platform is working as designed as per data. CC will face a revolt if she raises down here so surely a deal whether for 6000 or a new warhead altogether en route is my guess.